WO2000024399A1 - Compositions et procedes utilisant r(-) fluoxetine et autres composants actifs - Google Patents

Compositions et procedes utilisant r(-) fluoxetine et autres composants actifs Download PDF

Info

Publication number
WO2000024399A1
WO2000024399A1 PCT/US1999/024970 US9924970W WO0024399A1 WO 2000024399 A1 WO2000024399 A1 WO 2000024399A1 US 9924970 W US9924970 W US 9924970W WO 0024399 A1 WO0024399 A1 WO 0024399A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluoxetine
pharmaceutical composition
disorder
amount
biologically active
Prior art date
Application number
PCT/US1999/024970
Other languages
English (en)
Inventor
Timothy J. Barberich
Paul D. Rubin
Dean A. Handley
Original Assignee
Sepracor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc. filed Critical Sepracor Inc.
Priority to AU13219/00A priority Critical patent/AU1321900A/en
Publication of WO2000024399A1 publication Critical patent/WO2000024399A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Definitions

  • This invention relates to pharmaceutical compositions and methods of treatment or prevention employing two or more active ingredients.
  • the present invention encompasses pharmaceutical compositions which comprise, and methods which utilize, optically pure R(-) fluoxetine and a second biologically active compound, preferably, a benzodiazepine compound, a tricyclic antidepressant, a 5-HT 1A receptor antagonist, a 5- HT 3 receptor agonist, a ⁇ -adrenergic antagonist, an antipsychotic agent, an anti-anxiolytic or other psychotropic drug.
  • a second biologically active compound preferably, a benzodiazepine compound, a tricyclic antidepressant, a 5-HT 1A receptor antagonist, a 5- HT 3 receptor agonist, a ⁇ -adrenergic antagonist, an antipsychotic agent, an anti-anxiolytic or other psychotropic drug.
  • the present invention is well suitable for treating patients, having AIDS or HIV infection, cancer, cardiac disorder, post-myocardial depression, posttraumatic stress disorder or psychiatric disorder.
  • Fluoxetine N-methyl-3-phenyl-3-[ ( ⁇ , , ⁇ -trifluoro-p- tolyl) -oxy]-propylamine, is marketed as the hydrochloride salt form of the racemic mixture under the tradename PROZAC® (U.S. Patent 4,314,081).
  • PROZAC® is indicated for the treatment of depression, obsessive-compulsive disorder (OCD) and bulimia nervosa (Physician's Desk Reference® 52 Edition 1998, pages 859-860).
  • the racemic mixture of fluoxetine has certain disadvantages including headaches, nervousness, anxiety, insomnia, akathisia, severe anxiety leading to intense violent suicidal thoughts and self mutilation, manic behavior, nausea, diarrhea, drowsiness, decrease in libido, and/or sexual dysfunction.
  • the major disadvantage of the racemic mixture of fluoxetine is its long half-life and long duration of action. This long half life can lead to a buildup of fluoxetine in the patient's body and a concomitant increase in the above described side effects when a patient is given multiple doses. More importantly, its long half-life and long duration of action also makes it impossible or impractical to use the racemic mixture of fluoxetine as part of a combination therapy, although combination therapy might be very desirable.
  • R(-) fluoxetine and its use, is described in U.S. Patent Nos. 5,708,035 and 5,648,396 to Young et al. These patents state that the use of R(-) fluoxetine decreases the incidence of adverse effects seen with the racemic mixture of fluoxetine. These patents also state that R(-) fluoxetine is useful in the treatment of depression, migraine headaches, pain, in particular chronic pain, psychoactive substance abuse disorders and obsessive compulsive disorders. Additionally, U.S. Patent No. 5,648,396 discloses a method of treating depression in a human by first administering R(-) fluoxetine followed by a subsequent administration of a monoamine oxidase inhibitor.
  • U.S. Patent No. 5,356,934 discloses a method for treating sleep apnea in mammals which comprises administering to mammal requiring sleep apnea treatment an effective amount of (R) -fluoxetine or a pharmaceutically acceptable acid addition salt or solvate thereof.
  • U.S. Patent No. 4,035,511 discloses a method of producing analgesia or reducing hyperalgesia by administering racemic fluoxetine either alone or with morphine sulfate.
  • U.S. Patent No. 4,329,356 discloses a method for lowering blood pressure in a hypertensive mammal which comprises the co-administration of racemic fluoxetine and 1- 5-hydroxytryptophane, or preferably the co-administration of fluoxetine, 1-5-hydroxytryptophane and a peripheral decarboxylase inhibitor such as carbidopa[ ⁇ -hydrazino- ⁇ - methyl- ⁇ -(3, 4-dihydroxyphenyl) propionic acid monohydrate] or banserazide [n- (dl-seryl) -n"- (2,3,4- trihydroxybenzyl)hydrazine] .
  • a peripheral decarboxylase inhibitor such as carbidopa[ ⁇ -hydrazino- ⁇ - methyl- ⁇ -(3, 4-dihydroxyphenyl) propionic acid monohydrate] or banserazide [n- (dl-seryl) -n"- (2,3,4- trihydroxybenzyl)hydrazine] .
  • U.S. Patent No. 4,594,358 and U.S. Patent No. 4,683,235 discloses, respectively, a method of potentiating dextropropoxyphene or codeine analgesia in mammals, either alone or in combination with aspirin or acetaminophen, which comprises the administration of an effective amount of racemic fluoxetine or norfluoxetine prior to, concomitantly with, or after the administration of dextropropoxyphene or codeine which, if given alone, would produce less than the desired analgesic effect.
  • U.S. Patent No. 4,895,845 discloses a method of assisting weight loss in patients through the concomitant administration of a rauwolfia alkaloid and at least one antidepressant selected from the group consisting of aminoazales, phenoxyphenylpropylamine antidepressants such as fluoxetine, and aminopropiophenones, or preferably through the concomitant administration of a rauwolfia alkaloid, at least one antidepressant selected from the group consisting of aminoazales, phenoxyphenylpropylamines, and aminopropiophenones, and one or more of the sympathomimetic anorectic agents that have proved successful in some instances in promoting patient compliance to a calorically- restricted diet.
  • U.S. Patent No. 5,512,593 discloses a method of treating depression comprising administering to a patient an opioid antagonist selected from the group consisting of naltrexone, naloxone and a compound selected from the group consisting of one or more non-tricyclic antidepressants exhibiting serotonin reuptake inhibition in the synapses of the central nervous system such as bupropion, sertraline, fluoxetine, and trazodone.
  • an opioid antagonist selected from the group consisting of naltrexone, naloxone and a compound selected from the group consisting of one or more non-tricyclic antidepressants exhibiting serotonin reuptake inhibition in the synapses of the central nervous system such as bupropion, sertraline, fluoxetine, and trazodone.
  • U.S. Patent No. 5,527,788 discloses the use of DHEA and at least one anorectic agent, such as fenfluramine HC1, phentermine HC1, phendimetrazine tartrate, mazindol, diethylpropion HC1, and fluoxetine HC1, in combination to produce weight loss in animals.
  • anorectic agent such as fenfluramine HC1, phentermine HC1, phendimetrazine tartrate, mazindol, diethylpropion HC1, and fluoxetine HC1, in combination to produce weight loss in animals.
  • U.S. Patent No. 5,532,268, U.S. Patent No. 5,538,992 and U.S. Patent No. 5,552,429 discloses, respectively, a method for potentiating the action of fluoxetine, in increasing the availability of serotonin, norepinephrine and dopamine in the brain, comprising administering fluoxetine to a patient in need thereof in combination with a second component which is chosen from the group consisting of alprenolol, WAY 100135, spiperone, propranolol and tertatolol, pindolol, or a compound of the formula I that is described therein.
  • a second component which is chosen from the group consisting of alprenolol, WAY 100135, spiperone, propranolol and tertatolol, pindolol, or a compound of the formula I that is described therein.
  • WO 92/00103 discloses a pharmaceutical product comprising two or three active ingredients selected from a 5- HT 3 receptor antagonist, a 5-HT re-uptake inhibitor such as fluoxetine and a 5-HT x receptor agonist, as a combined preparation for simultaneous, separate or sequential use in therapy of depression and/or migraine.
  • compositions for the effective treatment of a variety of chronic and intractable disorders such as intractable coughing, dermatitis, chronic pain and tinnitus, which failed to respond to other treatments.
  • the compositions are a therapeutically effective dosage of dextromethorphan (DM) in combination with a therapeutically effective dosage of an inhibitor of enzymatic dextromethorphan oxidation by the liver enzyme debrisoquin hydroxylase.
  • DM dextromethorphan
  • antioxidants include yohimbine, fluoxetine, haloperidol, ajmaline, lobeline, pipamperone.
  • WO 96/09047 discloses a method of treating alcoholism and alcohol dependence in a mammal comprising administering to the mammal a therapeutically effective amount of a synergistic combination of at least one opioid antagonist, and at least one selective serotonin reuptake inhibitor.
  • selective serotonin reuptake inhibitor denotes compounds which enhance brain serotonergic activity by blocking the neuronal reuptake and subsequent inactivation of serotonin at synaptic junctions between nerve cells; such include fluoxetine, sertraline, paroxetine, venlafaxine, fluvoxamine, nefazodone, citalopram, and zimeldine.
  • WO 97/31629 discloses a method of treating disorders of sleep comprising administering to a patient in need of such treatment a first component chosen from the group consisting of fluoxetine, venlafaxin, citalopram, fluvoxamine, paroxetine, milnacipran and duloxetine in combination with a second component chosen from the group consisting of alprenolol, WAY 100135, WAY 100635, spiperone, pindolol, (S)- UH-301, penbutolol, propranolol, tertatolol, and a compound of the formula I as described therein.
  • a first component chosen from the group consisting of fluoxetine, venlafaxin, citalopram, fluvoxamine, paroxetine, milnacipran and duloxetine
  • a second component chosen from the group consisting of alprenolol, WAY 100135, WAY 100635, spiperone, pindolo
  • racemic fluoxetine in combination with other drugs for a number of uses.
  • advantages of racemic fluoxetine without the disadvantages of racemic fluoxetine such as the great potential for adverse drug-drug interactions.
  • the present invention encompasses a pharmaceutical composition which comprises an effective amount of optically pure R(-) fluoxetine, or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer, an effective amount of second biologically active compound and a pharmaceutically acceptable carrier.
  • the present invention also relates to a method of treating or preventing diseases or disorders in humans, especially a psychotic or psychiatric disease or disorder, using such pharmaceutical compositions.
  • the present invention also encompasses a method of treating or preventing a psychotic or psychiatric disease or disorder by administering optically pure R(-) fluoxetine and a second biologically active compound, preferably a benzodiazepine compound, a tricyclic antidepressant, an antipsychotic agent, an anti-anxiolytic, a ⁇ -adrenergic antagonist, a 5-HT 1A receptor antagonist, a 5-HT 3 receptor agonist, or a compound selected from the group consisting of buspirone, hydroxyzine, lorazepam, olanzapine, quetiapine, risperidone, 9-hydroxy-risperidone, sertindole, tomoxetine, valium and ziprasidone.
  • a second biologically active compound preferably a benzodiazepine compound, a tricyclic antidepressant, an antipsychotic agent, an anti-anxiolytic, a ⁇ -adrenergic antagonist
  • the present invention further encompasses methods of treating patients, having or at risk of having AIDS or HIV infection, cancer, cardiac disorder, post-myocardial depression, posttraumatic stress disorder or other psychiatric disorders, using optically pure R(-) fluoxetine in combination with one or more biologically active compounds.
  • the present invention encompasses methods of treating or preventing a psychotic or psychiatric disease or disorder which comprises administering an effective amount of R(-) fluoxetine and an amount of a biologically active 5-HT 1A receptor antagonist for a first period of time, and after the first period of time, administering an effective amount of R(-) fluoxetine and a reduced amount of said biologically active 5-HT 1A receptor antagonist for a second period of time; and kits to be used for such treatment or prevention.
  • the invention encompasses the use of R(-) fluoxetine, salts, solvates, hydrates and pro-drugs thereof in combination with one or more additional active ingredients.
  • R(-) fluoxetine can be used in the same pharmaceutical composition as the one or more additional active ingredient, or R(-) fluoxetine can be administered concurrently or sequentially with the other active ingredients, i.e., before, during or after.
  • the present invention does not contemplate a pharmaceutical composition containing an effective amount of optically pure R(-) fluoxetine and an effective amount of a monoamine oxidase inhibitor.
  • the present invention also does not encompass methods of treatment or prevention using optically pure R(-) fluoxetine in combination with a monoamine oxidase inhibitor. Specific preferred combinations and further details of the invention are described in detail below.
  • the present invention encompasses pharmaceutical compositions which comprise a therapeutically effective amount of R(-) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer, an effective amount of second biologically active compound, preferably, a benzodiazepine compound, a tricyclic antidepressant, an antipsychotic agent, a 5-HT 1A receptor antagonist such as pindolol, a 5-HT 3 receptor agonist, a ⁇ - adrenergic antagonist such as pindolol, an anti-anxiolytic, or a compound selected from the group consisting of buspirone, hydroxyzine, lorazepam, olanzapine, quetiapine, risperidone, 9-hydroxy-risperidone, sertindole, tomoxetine, valium and ziprasidone, and a pharmaceutically acceptable carrier.
  • a benzodiazepine compound preferably, a tricyclic antidepressant,
  • R(-) fluoxetine Any pharmaceutically acceptable salt of R(-) fluoxetine can be used in the present invention; however, acid addition salts are preferred.
  • the most preferred pharmaceutically acceptable salt of R(-) fluoxetine is the hydrochloride salt.
  • compositions and methods of this invention employ the optically pure R(-) isomer of fluoxetine in combination with drugs that act on the central nervous system (“CNS”) , such as 5-HT 1A receptor, including hypnotics and sedatives; drugs useful in treating psychiatric disorders, such drugs include antipsychotic or neuroleptic drugs, antianxiety drugs, antidepressants and mood-stabilizers; central nervous system stimulants such as amphetamines; dopamine receptor agonists; antimonic agents; antipanic agents; and antipsychotic agents and the like.
  • R(-) fluoxetine may also be used in combination with cardiovascular agents (beta blockers and ACE inhibitors) ; antivirals; antibiotics, antifungals; antineoplastics; and others.
  • R(-) fluoxetine can be used in a number of different patient populations including but not limited to cancer patients, cardiac patients, AIDS patients or HIV infected populations, and psychiatric patients, each of which is likely undergoing treatment with a drug other than racemic fluoxetine or is enantiomers.
  • many patients affiliated with life threatening diseases experience depression particularly at or about the time they first learned of their affliction. For example, victims of heart attacks are known to experience depression. Now these patients can be treated for their cardiac disorder as well as be treated for their depression while avoiding the adverse effects associated with the administration of racemic fluoxetine.
  • R(-) fluoxetine in combination with the drugs described herein provides an improved therapy over certain therapies presently available in the art; the use of R(-) fluoxetine and certain of the drugs may allow for treatment where none was previously available; and certain combinations can provide a synergistic benefit.
  • R(-) fluoxetine is used in combination with a benzodiazepine compound, a tricyclic antidepressant, an antipsychotic agent, an anti-anxiolytic, a ⁇ -adrenergic antagonist, a 5-HT 1A receptor antagonist, a 5-HT 3 receptor agonist, or one or more of the following compounds: buspirone, hydroxyzine, lorazepam, olanzapine, quetiapine, risperidone, 9-hydroxy-risperidone, sertindole, tomoxetine, valium and ziprasidone.
  • the preferred benzodiazepine compounds for use within the present invention include, but are not limited to, alprazola , brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepa , diazepa , estazola , flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam or triazolam.
  • the preferred tricyclic antipsychotic compounds for use within the present invention include, but are not limited to, chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine, trifluoperazine, chlorprothixene, thiothixene, clozapine, haloperidol, loxapine, molindone, pimozide, risperidone, 9-hydroxy-risperidone or desipramine.
  • the preferred 5-HT 1A receptor antagonists for use within the present invention include, but are not limited to, alprenolol, WAY 100135, spiperone, pindolol, (S)-UH-301, penbutolol, propranolol, tertatolol, and a compound of the formula I as disclosed in U.S. Patent No. 5,552,429, the content of which is herein incorporated by reference.
  • a pharmaceutical composition of the invention comprises from about 5 mg to about 100 mg of R(-) fluoxetine, and the second biologically active compound, which is a benzodiazepine compound, a tricyclic antidepressant, an antipsychotic agent, an anti-anxiolytic, a ⁇ -adrenergic antagonist, a 5-HT 1A receptor antagonist, a 5-HT 3 receptor agonist, or a compound selected from the group consisting of buspirone, hydroxyzine and valium, lorazepam, olanzapine, quetiapine, risperidone, 9-hydroxy-risperidone, sertindole, tomoxetine, valium and ziprasidone.
  • the dosage of the second biologically active compound can be easily determined by skilled artisans, e.g., following dosages recommended in the Physician's Desk Reference® 52 Edition 1998.
  • the R(-) fluoxetine is present in an amount on weight basis, relative to S(+) fluoxetine, from about 100:1 to about 10,000:1.
  • the present invention also relates to a method of treating or preventing a disease or disorder, especially a psychotic or psychiatric disease or disorder, using the above pharmaceutical composition.
  • the present invention further encompasses methods of treating or preventing a disease or disorder by administering R(-) fluoxetine in combination with a second biologically active compound which is a benzodiazepine compound, a tricyclic antidepressant, an anti-anxiolytic, a ⁇ -adrenergic antagonist, a 5-HT 1A receptor antagonist, a 5-HT 3 receptor agonist, or a compound selected from the group consisting of buspirone, hydroxyzine, lorazepam, olanzapine, quetiapine, risperidone, 9-hydroxy-risperidone, sertindole, tomoxetine, valium and ziprasidone.
  • a second biologically active compound which is a benzodiazepine compound, a tricyclic antidepressant,
  • the diseases or disorders that can be treated or prevented using R(-) fluoxetine and a benzodiazepine include, but are not limited to, depression, anxiety, alcohol withdrawal, preoperative apprehension, Lennox-Gastaut syndrome (petit mal variant) , bulimina nervosa, seizures, bipolar disorders, panic disorder, skeletal muscle spasm, spasticity caused by upper motor neuron disorders, athetosis and stiffman syndrome, convulsive disorders and insomnia.
  • R(-) fluoxetine and a tricyclic antipsychotic compound include, but are not limited to, anxiety, depression, nausea, vomiting, restlessness and apprehension before surgery, acute intermittent porphyria, tetanus, intractable hiccups, severe behavioral problems and hyperactivity in children, emotional withdrawal, conceptual disorganization, tension, hallucinatory behavior, suspiciousness and blunted affect in schizophrenic patients or Tourette's Disorder.
  • the diseases or disorders that can be treated or prevented using R(-) fluoxetine and a 5-HT 1A receptor antagonist include, but are not limited to, depression, obsessive-compulsive disorders, obesity and late luteal phase syndrome, hypertension, migraine, essential tremor, hypertrophic subaortic stenosis and pheochromocytoma.
  • the more preferred disease or disorder that can be treated or prevented using R(-) fluoxetine and a 5-HT 1A receptor antagonist includes, but is not limited to, posttraumatic depression disorder.
  • R(-) fluoxetine and a compound selected from the group consisting of buspirone, hydroxyzine, lorazepam, olanzapine, quetiapine, risperidone, 9-hydroxy-risperidone, sertindole, tomoxetine, valium and ziprasidone include, but are not limited to, anxiety, Attention Deficit Disorders, depression, hypertension, schizophrenia and psychotic disorders.
  • the disease or disorder that can be treated or prevented using R(-) fluoxetine and a ⁇ -adrenergic antagonist includes, but is not limited to, post myocardial infarction depression.
  • the preferred ⁇ -adrenergic antagonists include, but are not limited to, S(-) pindolol, penbutolol and propranolol.
  • the terms "substantially free of the S(+) stereoisomer” and “optically pure R(-) fluoxetine” means that the composition contains at least 90% by weight of R(-) fluoxetine and 10% by weight or less of S(+) fluoxetine. In the most preferred embodiment the "substantially free of the S(+) stereoisomer” means that the composition contains at least 99% by weight R(-) fluoxetine and 1% or less of S(+) fluoxetine.
  • R(-) fluoxetine can be asymmetrically synthesized or it can be resolved using conventional techniques, both of which are known in the art.
  • R(-) isomer of fluoxetine is disclosed in U.S. Patent Nos. 5,648,396 and 5,708,035, the contents of which are incorporated by reference.
  • benzodiazepine refers to the portion of the structure composed of a benzene ring (A) fused to a seven- membered diazepine ring (B) (Goodman & Gilman, The Pharmacological Basis of Therapeutics, 9th Ed.
  • benzodiazepines virtually all result from actions of these drugs on the CNS. The most prominent of these effects are sedation, hypnosis, decreased anxiety, muscle relaxation, anterograde amnesia, and anticonvulsant activity.
  • a variety of benzodiazepine-like effects have been observed in vivo and in vitro and have been classified as full agonistic effects (i . e . , faithfully mimicking agents such as diazepam with relatively low fractional occupancy of binding sites) or partial agonistic effects (i . e . , producing less intense maximal effects and/or requiring relatively high fractional occupancy compared to agents such as diazepam) .
  • benzodiazepines examples include, but are not limited to, alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, estazolam, flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam and triazolam (Goodman & Gilman, The Pharmacological Basis of Therapeutics, 9th Ed. McGraw-Hill, 1996, Chapter 17, p363, Table 17-1).
  • XANAX® tablets contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds (Physician's Desk Reference® 52 Edition 1998, page 2294).
  • the chemical name of alprazolam is 8-Chloro-l-methyl-6-phenyl-4H-s-triazolo[4,3- ⁇ ] [1,4]benzodiazepine.
  • XANAX Tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety.
  • LIBRIUM® chlordiazepoxide HC1 is 7-chloro-2- (methylamino) -5-phenyl-3H-l, 4-benzodiazepine 4-oxide hydrochloride (Physician's Desk Reference® 52 Edition 1998, page 2522) .
  • Librium is indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.
  • KLONOPIN® (clonazepam) is 5- (2-chlorophenyl) -1, 3- dihydro-7-nitro-2i ⁇ -l,4-benzodiazepin-2-one (Physician's Desk
  • Klonopin is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant) , akinetic and myoclonic seizures. Klonopin is also indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV.
  • TRANXENE® clorazepate dipotassium
  • VALIUM® (diazepam) is a benzodiazepine derivative. Chemically, diazepam is 7-chloro-l, 3-dihydro-l-methyl-5- phenyl-2H-l,4-benzodiazepin-2-one (Physician's Desk Reference® 52 Edition 1998, page 2527). Valium is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
  • PROSOMTM (estazolam tablets) is 8-chloro-6-phenyl-4H-s- triazolo[4-3- ⁇ ] [1,4]benzodiazepine (Physician's Desk Reference® 52 Edition 1998, pages 470-471) .
  • ProSom (estazolam) is indicated for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings .
  • ROMAZICON® flumazenil
  • flumazenil is a benzodiazepine receptor antagonist (Physician's Desk Reference® 52 Edition 1998, pages 2494-2495) .
  • flumazenil is ethyl 8-fluoro- 5 , 6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5- a] (l,4)benzodiazepine-3-carboxylate.
  • ROMAZICON is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose.
  • DALMANE® flurazepam hydrochloride is chemically 7- chloro-l-[2- (di-ethylamino) ethyl] -5- (o-fluorophenyl) -1,3- dihydro-2ff-l,4-benzodiazzepin-2-one dihydrochloride
  • ATIVAN® has the chemical formula, 7-chloro- 5- (o-chlorophenyl) -1, 3-dihydro-3-hydroxy-2i ⁇ -l, 4- benzodiazepin-2-one (Physician's Desk Reference® 52 Edition 1998, page 3013). Ativan (lorazepam) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
  • VERSED® (midazolam HC1) is 8-chloro-6- (2-fluorophenyl) - l-methyl-4H-imidazo[l,5-a] [1,4] benzodiazepine (Physician's
  • SERAX® (oxazepam) is the first of a chemical series of compounds known as the 3-hydroxybenzodiazepinones (Physician's Desk Reference® 52 Edition 1998, page 3132). Serax (oxazepam) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
  • DORAL® (quazepam) is a trifluoroethyl benzodiazepine hypnotic agent, having the chemical name 7-chloro-5- (o- fluoro-phenyl) -1, 3-dihydro-l- (2 ,2 ,2-trifluoroethyl) 2H-1,4- benzodiazepine-2-thione (Physician's Desk Reference® 52 Edition 1998, page 2958).
  • DORAL is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings .
  • RESTORIL® (temazepam) is a benzodiazepine hypnotic agent.
  • the chemical name is 7-chloro-l, 3-dihydro-3-hydroxy- l-methyl-5-ph.enyl-2.H-l, 4-benzodiazepin-2-one (Physician's
  • RESTORIL® (temazepam) is indicated for the short-term treatment of insomnia (generally 7-10 days) .
  • HALCION® Tablets contain triazolam, a triazologenzodiazepine hypnotic agent (Physician's Desk Reference® 52 Edition 1998, pages 2275-2276). HALCION is indicated for the short-term treatment of insomnia (generally 7-10 days) .
  • Antipsychotic agents are used primarily in the management of patients with psychotic or other serious psychiatric illness marked by agitation and impaired reasoning. These drugs have other properties that possibly are useful clinically, including antiemetic and antihistamine effects and the ability to potentiate analgesics, sedatives, and general anesthetics. Antipsychotic agents can also be used with optically pure R(-) fluoxetine. Tricyclic antipsychotic drugs fall into three subtypes: phenothiazines, thioxanthenes and other heterocyclic compounds.
  • phenothiazines include, but are limited to: THORAZINE® (chlorpromazine) , SERENTIL® (mesoridazine besylate) , MELLARIL® or MILLAZINE® (thioridazine) , TINDAL® (acetophenazine) , PERMITIL® or PROLIXIN® (fluphenazine) TRILAFON® (perphenazine) and STELAZINE® (trifluoperazine) (Goodman & Gilman, The Pharmacological Basis of Therapeutics, 9th Ed. McGraw-Hill, 1996, Chapter 18, p404, Table 18-1).
  • THORAZINE® (chlorpromazine) is 10- (3- dimethylaminopropyl) -2-chlorphenothiazine, a dimethylamine derivative of phenothiazine (Physician's Desk Reference® 52 Edition 1998, pages 2870-2871). THORAZINE® (chlorpromazine) is indicated, inter alia , for the management of manifestations of psychotic disorders.
  • SERENTIL® (mesoridazine besylate) is 10- [2 (l-methyl-2- piperidy1) ethyl] -2-methy1-syIfiny1) -phenothiazine (Physician's Desk Reference® 52 Edition 1998, pages 725-726).
  • Serentil® (mesoridazine besylate) is indicated in the treatment of, inter alia , emotional withdrawal, conceptual disorganization, anxiety, tension, hallucinatory behavior, suspiciousness and blunted affect in schizophrenic patients.
  • TRILAFON® (perphenazine) is (4- [3- (2-chlorophenothiazin- 10-yl)propyl-l-piperazineethanol) (Physician's Desk Reference® 52 Edition 1998, page 2666). TRILAFON® (perphenazine) is indicated for use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
  • STELAZINE® (trifluoperazine) is indicated for the management of the manifestations of psychotic disorders and for the short-term treatment of generalized non-psychotic anxiety (Physician's Desk Reference® 52 Edition 1998, page 2862) .
  • thioxanthenes include, but are limited to: TARACTAN® (chlorprothixene) and NAVANE® (thiothixene) (Goodman & Gilman, The Pharmacological Basis of Therapeutics, 9th Ed. McGraw-Hill, 1996, Chapter 18, p404, Table 18-1).
  • NAVANE® (thiothixene) is the cis isomer of N,N-dimethyl- 9-[3- (4-methyl-l-piperazinyl) -propylidene]thioxanthene-2- sulfonamide (Physician's Desk Reference® 52 Edition 1998, page 2192) .
  • NAVANE® (thiothixene) is indicated in the management of manifestations of psychotic disorders.
  • CLOZARIL® (clozapine) is a tricyclic dibenzodiazepine derivative, 8-chloro-ll- (4-methyl-l-piperazinyl) 5H- dibenzo[£>,e] [1, 4]diazepine (Physician's Desk Reference® 52
  • CLOZARIL® clozapine
  • HALDOL® (haloperidol) is 4- [4- (p-chlorophenyl) -4- hydroxy-piperidonol-4 ' -fluorobutyrophenone (Physician's Desk Reference® 52 Edition 1998, pages 1997-1998).
  • HALDOL® (haloperidol) is indicated, inter alia , for use in the management of manifestations of psychotic disorders, for the control of tics and vocal utterances of Tourette ' s Disorder in children and adults, for the treatment of severe behavior problems in children of combative.
  • LOXITANE® (loxapine) is 2-Chloro-ll- (4-methyl-l- piperazinyl) dibenz [b , f_ [1-4] oxaxepine (Physician's Desk
  • LOXITANE® loxapine
  • MOBAN® is 3-ethyl-6, 7-dihydro-2-methyl-5- (morpholinomethyl) indol-4 (5H) -one hydrochloride (Physician's Desk Reference® 52 Edition 1998, pages 976-977). MOBAN® (molindone) is indicated for the management of the manifestations of psychotic disorders.
  • ORAP® (Pimozide) is l-[ 1- [4 , 4-bis (4- fluorophenyl) butyl] 4-piperidinyl] -1, 3-dihydro-2#- benzimidazole-2-one (Physician's Desk Reference® 52 Edition 1998, page 978). ORAP® (Pimozide) is indicated for the suppression of motor and phonic tics in patients with Tarried's Disorder who have failed to respond satisfactorily to standard treatment.
  • RISPERDAL® (risperidone) is 3- [2- [4- (6-fluoro-1, 2- benzisoxazol-3-yl) -1-piperidinyl] ethyl] -6 ,7,8, 9-tetrahydro-2- methyl-4if-pyrido[l,2-a]pyrimidin-4-one (Physician's Desk
  • RISPERDAL® (risperidone) is indicated for the management of the manifestations of psychotic disorders. 9-hydroxy-risperidone is a major active metabolite of risperidone (Id.). This major metabolite has been reported to be approximately equi- effective as risperidone in Lacombe, Can . J. Psychiatry,
  • 9-hydroxy-risperidone can be prepared from risperidone or from other well known starting materials using synthetic techniques well known in the art.
  • NORPRAMIN® desipramine hydrochloride
  • Examples of 5-HT 1A receptor antagonists and/or ⁇ - adrenergic antagonists that can be used with R(-) fluoxetine in accordance with this invention include, but are limited to, alprenolol, WAY 100135, spiperone, VISKENTM (pindolol), (S)-UH-301, LEVATOLTM (penbutolol), INDERALTM (propranolol) and tertatolol.
  • Alprenolol (1- (1-methylethyl) amino-3-[2- (2- propenyl)phenoxy]-2-propanol) was disclosed by Brandstrom et al., U.S, Patent 3,466,325, which shows its preparation.
  • WAY 100135 N-(t-butyl)-3-[4-(2-methoxphenyl)piperazin- l-yl]-2-phenylpropanamide
  • Abou-Gharbia et al. U.S. Patent 4,988,814, which disclosed that the compound has affinity for the 5-HT 1A receptor. Cliffe et al., J . Med .
  • Spiperone (8- [4- (4-fluorophenyl) -4-oxobutyl] -1-phenyl- 1, 3 ,8-triazaspiro[4, 5]decan-4-one) is a well-known compound, taught in U.S. Patents 3,155,669 and 3,155,670. Its activity as a 5-HT 1A antagonist is shown by Middlmiss et al., Neurosci . and Biobehav . Rev . , 16:75-82, (1992).
  • Pindolol (4- (2-hydroxy-3-isopropylaminopropoxy) -indole) was disclosed by Troxler et al., U.S. Patent 3,471,515, which describes this compound as well as a beta-blocker. Dreshfield et al., Neurochem . Res . , 21(5) :557-562 (1996) disclosed that S(-) pindolol is a 5-HT 1A antagonist. VISKENTM (pindolol) is indicated in the management of hypertension (Physician's Desk Reference® 51 Edition 1997, page 2429). As used in the present application, the term "pindolol" refers to any acid addition salt or the free base, and includes either the racemic mixture or either of the R and S enantiomers.
  • Penbutolol (1- (t-butylamino) -2-hydroxy-3- (2-cyclopentyl- phenoxy) propane) was taught by Ruschig et al., U.S. Patent 3,551,493, which describes it as a beta-blocker. Both the (-) and the (+) enantiomers of penbutolol are of interest; the (-) enantiomer is preferred for the present purpose but both enantiomers and the racemic mixture are included in the word "penbutolol" in this document. LEVATOLTM (penbutolol) is indicated in the management of hypertension (Physician's Desk Reference® 51 Edition 1997, page 2547).
  • Propranolol ( l-isopropylamino-3- ( 1-naphthalenyloxy) -2- propanol) was disclosed by Crowther et al., U.S. Patent 3,337,628 to be a beta-blocker like tertatolol.
  • INDERALTM (propranolol) is indicated in the management of hypertension.
  • INDERALTM (propranolol) is also indicated in the management of myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis and pheochromocytoma (Physician's Desk Reference® 51 Edition 1997, pages 2833- 2834) .
  • Tertatolol (8- (3-t-butylamino-2-hydroxypropyloxy) - thiochro an) was disclosed by Malen et al., U.S. Patent 3,960,891, which teaches it to be a blocker of cardiac beta- adrenergic receptors. Its other activities, including the presently used 5-HT 1A antagonist activity, have been discovered since the original patents appeared.
  • non-benzodiazepine and non-tricyclic agents examples include, but are limited to: ZYPREXATM (olanzapine) , BUSPAR® (buspirone hydrochloride) , ATARAX® (hydroxyzine hydrochloride) , tomoxetine, SEROQUEL® (quetiapine) , sertindole and ziprasidone.
  • ZYPREXATM (olanzapine) is 2-methyl-4- (4-methyl-l- piperazinyl) -lOif-thieno [ 2 , 3-i»] [1,5] benzodiazepine
  • ZYPREXATM olanzapine
  • BUSPAR® buspirone hydrochloride
  • buspirone hydrochloride is an anti-anxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs (Physician's Desk Reference® 52 Edition 1998, page 782) .
  • Chemically, buspirone hydrochloride is 8-[4-[4- (2-pyrimidinyl) -l-piperazinyl]butyl]-8- azaspiro[4,5]decane-7,9-dione monohydrochlordie .
  • BUSPAR® buspirone hydrochloride
  • ADA Generalized Anxiety Disorder
  • ATARAX® hydroxyzine hydrochloride
  • ATARAX® hydroxyzine hydrochloride
  • quetiapine has recently approved by the FDA to manage the manifestations of psychotic disorders (Medical Sciences Bulletin, Issue No. 241 (1997)). Although the exact mechanism of quetiapine is unknown, it is generally believed that the antipsychotic action of quetiapine is largely due to antagonism at the dopamine and serotonin receptors (Arvanitis, et al., Biol .
  • Sertindole is designated chemically as l-[2-[4-[5- Chloro-1- (4-fluorophenyl) -lH-indol-3-yl] -l-piperdinyl] ethyl] - 2-imidazolidinone (The Merck Index, 12th Ed. , Merck & Co. ,
  • Sertindole can be prepared according to the procedures disclosed in U.S. Patent No. 4,710,500, the content of which is incorporated herein by reference. Sertindole is a new atypical antipsychotic agent for the treatment of schizophrenia (Brown, et al., Pharmacotherapy , 18(l):69-83 (1998)).
  • Ziprasidone is designated chemically as 5-[2-[4- (1,2- Benzisothiazol-yl) -l-piperazinyl]ethyl]-6-chloro-l, 3-dihydro- 2H-indol-2-one (The Merck Index, 12th Ed., Merck & Co., Inc.,
  • Ziprasidone can be prepared according to the procedures disclosed in U.S. Patent No. 4,831,031, the content of which is incorporated herein by reference. Ziprasidone is a novel antipsychotic agent that is in late clinical trials. It has shown antipsychotic efficacy in patients with schizophrenia and schizo-affective disorder and anxiolytic efficacy in patients about to undergo dental surgery (Davis and Markham, CNS Drugs , 8(2): 153-159
  • R(- fluoxetine/ziprasidone The magnitude of a prophylactic or therapeutic dose of R(-) fluoxetine, of course, vary with the nature of the severity of the condition to be treated and its route of administration. It will also vary according to the age, weight and response of the individual patient. In general the daily dose range of R(-) fluoxetine in treatment of diseases or disorders, especially psychotic or psychiatric diseases or disorders lie within the range from about 1 mg to about 100 mg per day, preferably about 5 mg to about 60 mg per day, and most preferably from about 10 mg to about 40 mg per day, in single or divided doses.
  • Effective amounts of the therapeutic agents to be used in combination with R(-) fluoxetine are based on the recommended doses known to those skilled in the art for the various diseases or disorders.
  • the daily dosage of alprazolam one of the preferred benzodiazepines, may range from about 0.25 mg to about 10 mg, preferably from about 2 mg to about 6 mg (Physicians' Desk Reference®, 53 rd Edition (1999) , pages 2516-2521) .
  • Alprazolam is commercially available, for example, as XANAX® tablets.
  • the daily dosage of chlorpromazine may range from about 10 mg to about 2,000 mg, preferably from about 100 mg to about 1000 mg (Physicians* Desk Reference®, 53 rd Edition (1999), pages 3101- 3104) .
  • Chlorpromazine is commercially available, for example, as THORAZINE® tablets.
  • the typical daily dosage of 9-hydroxy-risperidone, another preferred tricyclic antipsychotic agent and a major active metabolite of risperidone may range from about 0.25 mg to about 20 mg, preferably from about 1 mg to about 16 mg (Physicians' Desk Reference®, 53 rd Edition (1999) , pages 1432-1436) .
  • Risperidone is commercially available as RISPERDAL® tablets.
  • the daily dosage of penbutolol, one of the preferred ⁇ - adrenergic antagonists, may range from about 10 mg to about 80 mg, preferably from about 20 mg to about 40 mg (Physicians' Desk Reference®, 53 rd Edition (1999), pages 2908- 2910) .
  • Penbutolol is commercially available, for example, as LEVATOL® tablets.
  • the typical daily dosage for quetiapine may range from about 25 mg to about 800 mg, preferably from about 150 mg to about 750 mg (Physicians' Desk Reference®, 53 rd Edition (1999), pages 3428-3432); the daily dosage for sertindole may range from about 0.1 mg to about 700 mg, preferably from about 4 mg to about 24 mg (See, e.gr., U.S. Patent No.
  • the daily dosage for ziprasidone may range from about 5 mg to about 500 mg, preferably from about 50 mg to about 100 mg (See, e . g. , U.S.
  • Patent No. 4,831,031 to Lowe, III et al.
  • the attending physician would know how to and when to terminate, interrupt, or adjust therapy to lower dosage due to toxicity, bone marrow, liver or kidney dysfunctions or adverse drug-drug interaction. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response is not adequate (precluding toxicity) .
  • a therapeutically effective dose refers to that amount of the compound sufficient to result in amelioration of symptoms or a prolongation of survival in a patient.
  • an effective amount and the term “a therapeutically effective dose/amount” has the same meaning.
  • Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g. , for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population) .
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
  • Compounds which exhibit large therapeutic indices are preferred.
  • the data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 i.e., the concentration of the test compound which achieves a half- maximal inhibition of its target from infected cells compared to untreated control as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
  • an effective amount of R(-) fluoxetine and an effective amount of a biologically active 5-HT 1A receptor antagonist is administered for a first period of time; and then an effective amount of R(-) fluoxetine and a reduced amount of said biologically active 5-HT 1A receptor antagonist is administered for a second period of time.
  • 5-HT 1A receptor antagonist used herein is pindolol.
  • the first period of time is from about 2 to about 6 weeks and the second period of time is from about 2 to about 20 days.
  • a kit which comprises a plurality of dosage forms each comprising an effective amount of R(-) fluoxetine, a plurality of dosage forms each comprising an effective amount of a biologically active 5-HT 1A receptor antagonist, and a plurality of dosage forms each comprising a reduced amount of said biologically active 5-HT 1A receptor antagonist can be used in the above method.
  • a kit which comprises a single unit dosage form of an effective amount of R(-) fluoxetine, a single unit dosage form of an effective amount of a biologically active 5-HT 1A receptor antagonist, and a single unit dosage form of a reduced amount of said biologically active 5-HT 1A receptor antagonist can also be used in the above method.
  • Any suitable route of administration may be employed for providing the patient with an effective dosage of the pharmaceutical compositions of the present invention.
  • oral, rectal, parenteral, transdermal, sublingual subcutaneous, intramuscular, inhalation and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches and the like.
  • compositions of the present invention comprise R(-) fluoxetine and other active ingredients or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic acids including inorganic adds and organic acids.
  • R(-) fluoxetine one of the key component of the pharmaceutical composition of the present invention, is basic, salts may be prepared from pharmaceutically acceptable nontoxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobro ic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic and the like.
  • Particularly preferred are hydrobromic, hydrochloric, phosphoric and sulfuric acids.
  • compositions suitable for oral, rectal, parenteral including subcutaneous, intramuscular, and intravenous
  • parenteral including subcutaneous, intramuscular, and intravenous
  • the most preferred route of the present invention is oral. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.
  • the pharmaceutical carrier which is included in the pharmaceutical compositions of the present invention, may take a wide variety of forms depending on the form of preparation desired for administration, e.g. , oral or parenteral (including intravenous) .
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixir and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
  • the most preferred solid oral preparation is capsules. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired,
  • compositions of the present invention may also be administered by controlled release means and/or delivery devices such as those described in U.S. Pat. Nos. 3,536,809; 3,598,123; 3,630,200; 3,845,770; 3,847,770;
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion.
  • Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
  • a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a pour objet des compositions pharmaceutiques qui comprennent R(-) fluoxétine et un ou plusieurs autres composants biologiquement actifs. L'invention concerne aussi des procédés de traitement ou de prévention d'une maladie ou d'un trouble, notamment du type psychotique ou psychiatrique, au moyen de la composition pharmaceutique susmentionnée ou par l'administration de R(-) fluoxétine en combinaison avec un ou plusieurs autres composants biologiquement actifs. L'invention concerne enfin des procédés de traitement des patients présentant des risques d'infection par le SIDA ou par le VIH, de cancer, de dysfonctionnement cardiaque, de dépression post-infarctus ou de syndrome de stress post-traumatique au moyen de R(-) fluoxétine optiquement pure combinée à un ou plusieurs autres composants biologiquement actifs.
PCT/US1999/024970 1998-10-23 1999-10-22 Compositions et procedes utilisant r(-) fluoxetine et autres composants actifs WO2000024399A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13219/00A AU1321900A (en) 1998-10-23 1999-10-22 Compositions and methods employing r(-) fluoxetine and other active ingredients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17770398A 1998-10-23 1998-10-23
US09/177,703 1998-10-23

Publications (1)

Publication Number Publication Date
WO2000024399A1 true WO2000024399A1 (fr) 2000-05-04

Family

ID=22649648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/024970 WO2000024399A1 (fr) 1998-10-23 1999-10-22 Compositions et procedes utilisant r(-) fluoxetine et autres composants actifs

Country Status (2)

Country Link
AU (1) AU1321900A (fr)
WO (1) WO2000024399A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1238676A1 (fr) * 2001-03-01 2002-09-11 Pfizer Products Inc. Combinaison d'un inhibiteur de la recapture de la sérotonine et d'un antipsychotique atypique pour l'utilisation dans la dépression, les troubles obsessionnels compulsifs et les psychoses
EP1859807A1 (fr) * 2005-03-04 2007-11-28 Tokyo Medical and Dental University Agent therapeutique de prevention de la recurrence d une psychose ou d une schizophrenie induite par psychostimulant
EP2052251A1 (fr) * 2006-07-27 2009-04-29 Janssen Pharmaceutica N.V. Multithérapie avec antagoniste du récepteur 5-ht7 et inhibiteur du recaptage de la sérotonine
US8618288B2 (en) 2003-09-17 2013-12-31 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
WO2015120317A1 (fr) * 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Compositions pharmaceutiques comprenant un médicament antipsychotique et un inhibiteur de vmat2 et utilisations de celles-ci
US10844058B2 (en) 2015-10-30 2020-11-24 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
US10857148B2 (en) 2017-10-10 2020-12-08 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US10857137B2 (en) 2017-01-27 2020-12-08 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US10906903B2 (en) 2015-12-23 2021-02-02 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US11026939B2 (en) 2017-09-21 2021-06-08 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US11026931B2 (en) 2018-08-15 2021-06-08 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0830864A1 (fr) * 1996-09-23 1998-03-25 Eli Lilly And Company Thérapie combinée pour le traitement de psychoses
WO1999061014A2 (fr) * 1998-05-28 1999-12-02 Sepracor Inc. Compositions et methodes utilisant de la r(-) fluoxetine et d'autres ingredients actifs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0830864A1 (fr) * 1996-09-23 1998-03-25 Eli Lilly And Company Thérapie combinée pour le traitement de psychoses
WO1999061014A2 (fr) * 1998-05-28 1999-12-02 Sepracor Inc. Compositions et methodes utilisant de la r(-) fluoxetine et d'autres ingredients actifs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A A H P MEGENS ET AL: "In Vivo Pharmacological Profile of 9-Hydroxyrisperidone, the Major Metabolite of the Novel Antipsychotic Risperidone", DRUG DEVELOPMENT RESEARCH,US,NEW YORK, NY, vol. 33, no. 4, December 1994 (1994-12-01), pages 399 - 412-412, XP002110094, ISSN: 0272-4391 *
BACH MICHAEL ET AL: "Ritanserin as adjunct to fluoxetin treatment of OCD patients with psychotic features.", PHARMACOPSYCHIATRY 1997, vol. 30, no. 1, 1997, pages 28 - 29, XP000901154, ISSN: 0176-3679 *
MISRA L K ET AL: "Quetiapine: a new atypical antipsychotic.", SOUTH DAKOTA JOURNAL OF MEDICINE, (1998 JUN) 51 (6) 189-93. REF: 13, XP000901163 *
OLESEN O.V. ET AL: "Serum concentrations and side effects in psychiatric patients during risperidone therapy.", THERAPEUTIC DRUG MONITORING, (1998) 20/4 (380-384)., XP000901159 *
SAXENA S ET AL: "RISPERIDONE AUGMENTATION OF SRI TREATMENT FOR REFRACTORY OBSESSIVE-COMPULSIVE DISORDER", JOURNAL OF CLINICAL PSYCHIATRY,XX,XX, vol. 57, no. 7, 1 July 1996 (1996-07-01), pages 303 - 306, XP002052520 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1238676A1 (fr) * 2001-03-01 2002-09-11 Pfizer Products Inc. Combinaison d'un inhibiteur de la recapture de la sérotonine et d'un antipsychotique atypique pour l'utilisation dans la dépression, les troubles obsessionnels compulsifs et les psychoses
US8618288B2 (en) 2003-09-17 2013-12-31 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP1859807A1 (fr) * 2005-03-04 2007-11-28 Tokyo Medical and Dental University Agent therapeutique de prevention de la recurrence d une psychose ou d une schizophrenie induite par psychostimulant
EP1859807A4 (fr) * 2005-03-04 2008-04-23 Univ Tokyo Medical & Dental Agent therapeutique de prevention de la recurrence d une psychose ou d une schizophrenie induite par psychostimulant
US8883808B2 (en) 2005-08-04 2014-11-11 Janssen Pharmaceutica N.V. Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy
EP2052251A1 (fr) * 2006-07-27 2009-04-29 Janssen Pharmaceutica N.V. Multithérapie avec antagoniste du récepteur 5-ht7 et inhibiteur du recaptage de la sérotonine
EP2052251A4 (fr) * 2006-07-27 2011-07-06 Janssen Pharmaceutica Nv Multithérapie avec antagoniste du récepteur 5-ht7 et inhibiteur du recaptage de la sérotonine
US9782398B2 (en) 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
EP4049681A1 (fr) * 2014-02-07 2022-08-31 Neurocrine Biosciences, Inc. Compositions pharmaceutiques comprenant un médicament antipsychotique et un inhibiteur de vmat2 et leurs utilisations
WO2015120317A1 (fr) * 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Compositions pharmaceutiques comprenant un médicament antipsychotique et un inhibiteur de vmat2 et utilisations de celles-ci
US10844058B2 (en) 2015-10-30 2020-11-24 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
US10851103B2 (en) 2015-10-30 2020-12-01 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
US10851104B2 (en) 2015-10-30 2020-12-01 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
US10906902B2 (en) 2015-12-23 2021-02-02 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
US10919892B2 (en) 2015-12-23 2021-02-16 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
US10906903B2 (en) 2015-12-23 2021-02-02 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
US10874648B2 (en) 2017-01-27 2020-12-29 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US10912771B1 (en) 2017-01-27 2021-02-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US10857137B2 (en) 2017-01-27 2020-12-08 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US10952997B2 (en) 2017-01-27 2021-03-23 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US11040029B2 (en) 2017-01-27 2021-06-22 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US11439629B2 (en) 2017-01-27 2022-09-13 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US11026939B2 (en) 2017-09-21 2021-06-08 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US11311532B2 (en) 2017-09-21 2022-04-26 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US10857148B2 (en) 2017-10-10 2020-12-08 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US11654142B2 (en) 2017-10-10 2023-05-23 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US11026931B2 (en) 2018-08-15 2021-06-08 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Also Published As

Publication number Publication date
AU1321900A (en) 2000-05-15

Similar Documents

Publication Publication Date Title
US20020151543A1 (en) Compositions and methods employing R (-) fluoxetine and other active ingredients
US6538034B2 (en) Methods of treating or preventing weight gain, obesity, and related disorders
CA2548917C (fr) Combinaison d'un sedatif et d'un modulateur des neurotransmetteurs, et methodes permettant d'ameliorer la qualite du sommeil et de traiter la depression
TW200803901A (en) Methods of treating anxiety disorders
EP1246789B1 (fr) Procede de preparation de (r)- et (s)- didesmethylsibutramine optiquement pures
WO2000024399A1 (fr) Compositions et procedes utilisant r(-) fluoxetine et autres composants actifs
WO1999061014A2 (fr) Compositions et methodes utilisant de la r(-) fluoxetine et d'autres ingredients actifs
US6339106B1 (en) Methods and compositions for the treatment and prevention of sexual dysfunction
CN101472571B (zh) 毒蕈碱型受体m1拮抗剂在制备治疗心理学病况药物中的应用
AU2001289062A1 (en) Methods and compositions for the treatment and prevention of sexual dysfunction
RU2358719C2 (ru) Композиции, содержащие ингибиторы обратного захвата допамина, и способы их применения
ZA200101498B (en) Methods of using and compositions comprising dopamine reuptake inhibitors.
US6974838B2 (en) Methods of treating or preventing pain using sibutramine metabolites
AU2007200334A1 (en) Methods of using and compositions comprising dopamine reuptake inhibitors

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 13219

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase